I'm with you box, will add some this month. Teva's MS drug is dead, so its priorities will be focused on 011. OGXI's pipeline just got added importance in Teva's future to develop branded drugs. Nothing has changed in the landscape, just becoming clearer cheaper and effective drugs will dominate. USA, welcome to the rest of the world.